{"id":1701,"date":"2022-11-21T13:43:25","date_gmt":"2022-11-21T12:43:25","guid":{"rendered":"https:\/\/avextra.com\/?page_id=1701"},"modified":"2026-03-06T11:50:53","modified_gmt":"2026-03-06T10:50:53","slug":"media","status":"publish","type":"page","link":"https:\/\/avextra.com\/en\/ueber-avextra\/media\/","title":{"rendered":"Media"},"content":{"rendered":"
Home<\/a><\/span><\/span>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Press Releases<\/h1>\n\n\n\n

Please find the latest press releases from Avextra here.<\/p>\n<\/div>\n\n\n\n

\n
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>
\"Neues<\/a><\/div>

Neues Dronabinol-Konzentrat optimiert Rezepturherstellung in der Apotheke<\/a><\/h3>

Bensheim, 5. Mai 2026 \u2013 Avextra erweitert mit dem Dronabinol Konzentrat Avextra 31 mg\/ml sein Portfolio an cannabisbasierten Rezepturarzneimitteln…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Novel<\/a><\/div>

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance<\/a><\/h3>

Bensheim, Germany, December 3rd 2025 \u2014 How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases<\/a><\/h3>

First patient enrolled in randomized, placebo-controlled study\n\nBensheim, 24. October 2025 \u2013 Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently...<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"First<\/a><\/div>

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial<\/a><\/h3>

Bensheim, Germany, August 11, 2025 \u2013\u00a0PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients<\/a><\/h3>

Bensheim, Germany, 13th June 2025 \u2014 New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Veteran<\/a><\/div>

Veteran Banker Joins Avextra\u2019s Supervisory Board<\/a><\/h3>

Bensheim, Germany, April 3, 2025 \u2013 Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra\u2019s Supervisory Board,…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Showcases Study Findings on World Sleep Day 2025<\/a><\/h3>

Bensheim, Germany \u2013 14 March 2025 \u2013 In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Unveils Promising Study Results at Major Pain Congress<\/a><\/h3>

Bensheim, Germany \u2013 13 March 2025 \u2013 At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div><\/div>